Proteotype Diagnostics Joins EU-Funded HER-CARE Network for Breast Cancer Research

Proteotype Diagnostics has been selected as an industrial beneficiary in the HER-CARE Doctoral Network, a European Union-funded research program focused on hereditary and early-stage breast cancer, announced in a press release. The network is supported by the EU's Horizon Europe programme under the Marie Skłodowska-Curie Actions.

The HER-CARE consortium includes major academic and clinical partners such as Karolinska Institutet, University of Cambridge, the Institute of Cancer Research in London, Institut Gustave Roussy, the Netherlands Cancer Institute, and the Medical University of Vienna. The program aims to integrate genomics, proteomics, imaging, and clinical data science to improve early detection, risk assessment, and treatment strategies.

As part of the project, Proteotype Diagnostics will recruit a doctoral candidate for a three-year PhD focused on developing circulating proteomic biomarkers for early breast cancer detection and prediction of treatment response. The researcher will be employed by Proteotype and enrolled at the Medical University of Vienna under the supervision of Dr. Yen Tan and Dr. Klaus Kratochwill.

The work builds on Proteotype’s proprietary proteomic biomarker platform, which measures amino acid resolved protein signatures in blood samples. The platform has shown potential in detecting early-stage breast cancer and predicting response to cyclin-dependent kinase 4/6 inhibitor therapies. Recruitment for the PhD position is expected to begin in autumn 2026.